Hyperion DeFi (NASDAQ:HYPD) Given New $7.30 Price Target at Chardan Capital

Hyperion DeFi (NASDAQ:HYPD) had its price objective cut by analysts at Chardan Capital from $8.25 to $7.30 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s target price suggests a potential upside of 144.15% from the stock’s previous close.

A number of other research analysts have also recently commented on HYPD. Weiss Ratings restated a “sell (e+)” rating on shares of Hyperion DeFi in a research note on Wednesday, May 20th. Zacks Research cut shares of Hyperion DeFi from a “hold” rating to a “strong sell” rating in a research note on Monday, March 30th. Finally, Cantor Fitzgerald upgraded shares of Hyperion DeFi to a “strong-buy” rating in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.65.

Hyperion DeFi Price Performance

HYPD stock opened at $2.99 on Monday. Hyperion DeFi has a twelve month low of $2.11 and a twelve month high of $17.18. The company has a market cap of $45.32 million, a PE ratio of -0.30 and a beta of 2.47. The business’s 50-day simple moving average is $3.65 and its 200 day simple moving average is $3.62. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12.

Hyperion DeFi (NASDAQ:HYPD) last released its earnings results on Thursday, March 26th. The company reported ($7.76) earnings per share for the quarter. The company had revenue of $0.50 million during the quarter. On average, research analysts anticipate that Hyperion DeFi will post 1.78 earnings per share for the current year.

Insider Activity

In other news, insider Hyunsu Jung bought 7,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was bought at an average price of $3.70 per share, for a total transaction of $25,900.00. Following the completion of the purchase, the insider owned 1,384,676 shares of the company’s stock, valued at approximately $5,123,301.20. The trade was a 0.51% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $38,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $73,000. Formidable Asset Management LLC bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $83,000. Finally, State Street Corp bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $92,000. Institutional investors own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.